News

Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition
Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...
Ozempic maker Novo Nordisk on track for its worst day since Black Monday
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Who is Maziar Mike Doustdar? Novo Nordisk names new CEO to tackle ‘market challenges’
Novo Nordisk has appointed Maziar Mike Doustdar as CEO, replacing Lars Fruergaard, to address recent market challenges.
Novo Nordisk Shares Plummet as Competition Weighs on Sales
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Novo Nordisk appoints new CEO Maziar Doustdar
July 29 (UPI) -- Novo Nordisk announced Tuesday that Mike Doustdar has been appointed as the company's new CEO. Doustdar ...
NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?
Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...
Explore more
Stock Movers: Novo Nordisk, Palo Alto, Union Pacific
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Novo Nordisk: Massive Overreaction Presents An Opportunity
Novo Nordisk selloff is an overreaction. With solid fundamentals, a strong drug pipeline & long-term upside, discover why ...